Oslo, 21 December 2023 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and
reliable provider of high-quality products to hospitals and pharmacies, today
announces it has renewed its contract with Vitaflo International Limited
(Vitaflo International), granting Navamedic the exclusive rights to market and
distribute Vitaflo International's medical nutrition products across the Nordic
region for an additional five years.
This agreement follows a longstanding partnership between Navamedic and Vitaflo
International, dating back to 2005. Vitaflo International's medical nutrition
products make up Navamedic's IEM (inborn error of metabolism) products and are
part of the Hospital segment.
"We are thrilled to have renewed the contract with Vitaflo International, which
underpins the strength of Navamedic's marketing and distribution channels in the
Nordics. The medical nutrition product portfolio represents one of Navamedic's
key product offerings to our customers in the Nordics, and we look forward to
continuing our collaboration and partnership with Vitaflo International,"
commented Kathrine Gamborg Andreassen, CEO of Navamedic.
For further information, please contact:
Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com
Lars Hjarrand, CFO, Navamedic
Mobile: +47917 62 842
E-mail: lars.hjarrand@navamedic.com
About Navamedic
Navamedic ASA is a full-service provider of high-quality healthcare products to
hospitals and pharmacies. Navamedic meets the specific medical needs of patients
and consumers by leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in all the Nordic
countries, the Baltics and Benelux, with sales representation in the UK and
Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange (ticker: NAVA). For more information, please visit Navamedic.com.